Abstract
Monotherapy in newly diagnosed epilepsy: levetiracetam versus standard anticonvulsants.
Highlights
Keppra Versus Older Monotherapy in Epilepsy Trial (KOMET): An Unblinded, Randomised, Two Parallel-Group, Stratified Trial Comparing the Effectiveness of Levetiracetam With Controlled-Release Carbamazepine and Extended-Release Sodium Valproate as Monotherapy in Patients With Newly Diagnosed Epilepsy
The target doses of each medication (LEV 1000 mg/d, valproic acid (VPA)-ER 1000 mg/d, and CBZ-CR 600 mg/d) were reached in 2 weeks, and further titration depended on the clinical situation with maximum doses of each medication set a priori: LEV 3000 mg/d, VPA-ER 2000 mg/d, and CBZ-CR 1600 mg/d)
The primary outcome measure was time to withdrawal from treatment with the aim of comparing LEV with the other two standard antiseizure medication (ASM), and the primary analysis was by intention-to-treat
Summary
KOMET: An Unblinded, Randomised, Two Parallel-Group, Stratified Trial Comparing the Effectiveness of Levetiracetam With Controlled-Release Carbamazepine and Extended-Release Sodium Valproate as Monotherapy in Patients With Newly Diagnosed Epilepsy. The authors divided newly diagnosed patients with epilepsy into two arms, one in which valproic acid (VPA) was considered the best-recommended treatment, and the other in which CBZ was considered best. Levetiracetam Versus Standard Antiseizure Medications tion of valproic acid (VPA-ER) versus LEV, and the other into CBZ-CR versus LEV.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
